Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviours and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations

• MeSH
• chronická hepatitida B diagnóza   MeSH
• chronická hepatitida C diagnóza   MeSH
• Publikační typ
• směrnice MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• infekční lékařství
• NLK Publikační typ
• publikace WHO

The field of HCV therapeutics continues to evolve rapidly and, since the World Health Organization (WHO) issued its first Guidelines for the screening, care and treatment of persons with hepatitis C infection in 2014, several new medicines have been approved by at least one stringent regulatory authority. These medicines, called direct-acting antivirals (DAAs), are transforming the treatment of HCV, enabling regimens that can be administered orally, are of shorter duration (as short as eight weeks), result in cure rates higher than 90%, and are associated with fewer serious adverse events than the previous interferon- containing regimens. WHO is updating its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines. The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient's HCV genotype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014

• MeSH
• hepatitida C * diagnóza   terapie   MeSH
• Publikační typ
• směrnice pro lékařskou praxi MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• infekční lékařství
• NLK Publikační typ
• publikace WHO

These are the first World Health Organization (WHO) guidelines for the prevention, care and treatment of persons living with chronic hepatitis B (CHB) infection, and complement similar recently published guidance by WHO on the prevention, care and treatment of infection due to the hepatitis C virus (HCV). The recommendations in these guidelines promote the use of simple, non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of nucleos(t)ide analogues with a high barrier to drug resistance (tenofovir and entecavir, and entecavir in children aged 2-11 years) for first- and second-line treatment. Recommendations for the treatment of HBV/HIV-coinfected persons are based on the WHO 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, which will be updated in 2015. These recommendations provide opportunities to save lives, improve clinical outcomes of persons living with CHB, reduce HBV incidence and transmission, and stigma due to disease, but they also pose practical challenges to policymakers and implementers in low- and middle-income countries.--Publisher description.

• MeSH
• chronická hepatitida B * farmakoterapie   prevence a kontrola   MeSH
• játra patofyziologie   MeSH
• Publikační typ
• směrnice pro lékařskou praxi MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• infekční lékařství
• NLK Publikační typ
• publikace WHO

• MeSH
• antiretrovirové látky terapeutické užití   MeSH
• HIV infekce farmakoterapie   prevence a kontrola   MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• dermatovenerologie
• infekční lékařství
• NLK Publikační typ
• publikace WHO

• MeSH
• primární zdravotní péče MeSH
• směrnice jako téma MeSH
• veřejné zdravotnictví MeSH
• Publikační typ
• směrnice MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• veřejné zdravotnictví

• MeSH
• management nemoci MeSH
• primární zdravotní péče MeSH
• směrnice jako téma MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• veřejné zdravotnictví

• MeSH
• primární zdravotní péče MeSH
• řízení zdravotnictví MeSH
• směrnice pro lékařskou praxi jako téma MeSH

• Konspekt
• Veřejné zdraví a hygiena
• NLK Obory
• management, organizace a řízení zdravotnictví

• Klíčová slova
• organizace péče nemocniční, kvalita péče, zdravotnictví veřejné, směrnice,

• NLK Obory
• management, organizace a řízení zdravotnictví
• veřejné zdravotnictví